1. Home
  2. NSTS vs CGTX Comparison

NSTS vs CGTX Comparison

Compare NSTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NSTS Bancorp Inc.

NSTS

NSTS Bancorp Inc.

N/A

Current Price

$14.06

Market Cap

66.6M

Sector

Finance

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$1.06

Market Cap

79.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSTS
CGTX
Founded
1921
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.6M
79.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NSTS
CGTX
Price
$14.06
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
13.1K
343.0K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
$252,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.73
$0.55
52 Week High
$14.19
$2.05

Technical Indicators

Market Signals
Indicator
NSTS
CGTX
Relative Strength Index (RSI) 63.41 53.18
Support Level $13.70 $1.02
Resistance Level N/A $1.18
Average True Range (ATR) 0.06 0.05
MACD -0.00 0.00
Stochastic Oscillator 40.91 59.09

Price Performance

Historical Comparison
NSTS
CGTX

About NSTS NSTS Bancorp Inc.

NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: